| 1.04 -0.1 (-8.77%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.74  |
1-year : | 2.08 |
| Resists | First : | 1.49 |
Second : | 1.78 |
| Pivot price | 1.36 |
|||
| Supports | First : | 1.01 |
Second : | 0.84 |
| MAs | MA(5) : | 1.18 |
MA(20) : | 1.41 |
| MA(100) : | 1.69 |
MA(250) : | 2.06 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 2.9  |
D(3) : | 2.8 |
| RSI | RSI(14): 25.6 |
|||
| 52-week | High : | 3.65 | Low : | 0.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NMRA ] has closed below the lower bollinger band by 1.2%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 35.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.17 - 1.18 | 1.18 - 1.19 |
| Low: | 1 - 1.01 | 1.01 - 1.02 |
| Close: | 1.02 - 1.05 | 1.05 - 1.06 |
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Mon, 15 Jun 2026
Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update - Yahoo Finance
Thu, 28 May 2026
NMRA - Finviz
Mon, 05 Jan 2026
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - Yahoo Finance
Thu, 13 Mar 2025
Class Action Filed Against Neumora Therapeutics, Inc. - GlobeNewswire
Thu, 13 Feb 2025
NMRA Investor Reminder: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 188 (M) |
| Shares Float | 116 (M) |
| Held by Insiders | 23.2 (%) |
| Held by Institutions | 60.1 (%) |
| Shares Short | 7,990 (K) |
| Shares Short P.Month | 7,790 (K) |
| EPS | -1.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -73.9 % |
| Return on Equity (ttm) | -187.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -181 (M) |
| Levered Free Cash Flow | -99 (M) |
| PE Ratio | -0.85 |
| PEG Ratio | 0 |
| Price to Book value | 4.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|